The Use of Prothrombin Complex Concentrates: Results of a Nationwide Survey of Critical Care Pharmacists.

BACKGROUND

Prothrombin complex concentrates (PCCs) are frequently used.

OBJECTIVE

To elucidate practices and perceptions of proprietary and nonproprietary PCCs use.

METHODS

An electronic pretested cross-sectional survey e-mailed thrice to 1 critical care pharmacist at 1170 US institutions. Questions addressed hospital and pharmacy characteristics, use of PCCs, and perceptions of effectiveness and safety.

RESULTS

429 (39.5%) of 1086 eligible institutions completed the questionnaire. PCCs were used several times per month to several times per week (62.6%). An order set was routinely or always used to direct PCCs usage at 66.4% of institutions. Four-factor PCCs were preferred by 93% of institutions. The most common perceived indications for 4-factor PCCs were hemorrhage related to warfarin (92.1%) or oral Xa inhibitors (81.8%), intracranial hemorrhage (78.4%), trauma hemorrhage (66.2%), surgical hemorrhage (61.1%), and refractory hemorrhage (57.3%). The most common perceived contraindications were heparin-induced thrombocytopenia (42%), disseminated intravascular coagulopathy (39.2%), and active thromboembolism (38.9%). Most institutions considered patient weight (78.8%), indication (77.6%), and International Normalized Ratio (76.9%) when dosing PCCs. Only 43.8% of institutions used fixed dose, only 19.6% compounded PCCs at the bedside, and only 11.9% administered PCCs by rapid infusion. Compared to standard blood products, respondents believed PCCs acted more rapidly, were less likely to cause volume issues, and were more expensive. Respondents were neutral about PCCs acting longer, being more effective at preventing or treating hemorrhage, or causing thromboembolism.

CONCLUSIONS

Off-label use of PCCs is common. Differing perceptions surrounding indications, contraindications, and comparisons to blood products/procoagulants likely contribute to variable practices.